Clinical Trial

Adjuvant Cerebroprotection Using Normobaric Hyperoxia in Pre-hospital Patients with Suspected Stroke

Study acronym: AN-O2-EMS
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to determine the efficacy and safety of inhaled normobaric hyperoxia therapy (NBO) beginning in the pre-hospital setting in patients with suspected acute cerebral ischemia (ACI) due to large vessel occlusion presenting within 6 hours of symptom onset.
Trial Details
NCT Number NCT06801457
Lead Sponsor Capital Medical University
Conditions Stroke Acute
Enrollment 1,000 participants
Start Date 2025-02-01
Primary Completion 2028-01-30 (estimated)
Study Completion 2028-01-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-30